Clinical Trials
3 trialsNCT05522387 2026-02-27
An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease
Inmune Bio, Inc.
Phase 2 Terminated
NCT06723015 2025-11-18
Tau PET Outcomes With Anti-amyloid Immunotherapies
Mayo Clinic
Phase 2 Enrolling by invitation
NCT05321498 2023-09-28
Study to Assess the Efficacy of XPro1595 in Patients With Mild Cognitive Impairment With Biomarkers of Inflammation
Inmune Bio, Inc.
Phase 2 Withdrawn